10.11.2015 • News

Court Says Mylan Can Uphold Perrigo Bid

A federal district court judge in New York has ruled that Mylan can continue its hostile takeover bid for Perrigo. In the case heard by the court, Perrigo claimed Mylan had made false statements by saying it expects the merged companies to see at least $800 million in pretax revenues by the end of the fourth year. However, Judge Naomi Reice Buchwald ruled that Mylan had conducted a “sound process” in devising the estimate.

Mylan has offered $75 in cash and 2.3 ordinary shares for each Perrigo ordinary share. As of September, the deal was valued at $27 billion. The Netherlands-headquartered drugmaker will be able to move forward with the acquisition if the majority of Perrigo shareholders tender their shares by Nov.13. Perrigo said it does not plan to appeal the ruling.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.